Work Here?
Work Here?
Work Here?
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Irving, Texas
Founded
1992
Medpace provides clinical development services for the biotechnology, pharmaceutical, and medical device industries. They conduct clinical trials from Phase I to Phase IV, which means they help test new drugs and therapies at various stages of development. Their services include managing the trials, ensuring compliance with regulations, and analyzing the results. Medpace stands out from competitors by focusing on a high-science approach and having deep expertise in specific therapeutic areas like oncology and cardiology. The company's goal is to speed up the development of safe and effective medical treatments worldwide.
đź’ˇ Want to apply to Medpace, Inc.?
You have ways to get a Medpace, Inc. referral from your network.
Get referrals →
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$924.3M
Above
Industry Average
Funded Over
2 Rounds
Flexible Work Hours
Unlimited Paid Time Off
Competitive Compensation and Benefits Package
Employee Health and Wellness Initiatives
Hybrid Work Options
Structured Career Paths with Opportunities for Professional Growth
Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.
STOCKHOLM, Aug. 15, 2024 /PRNewswire/ - Skanska has signed a contract with Medpace, a clinical research company, for the construction of a new office building in Cincinnati, Ohio, USA.
First National Bank of Hutchinson invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP).
Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%.Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter of 2023 and 2022, respectively.EBITDA was $95.8 million for the fourth quarter of 2023, an increase of 19.2% from EBITDA of $80.4 million for the comparable prior-year period, resulting in an EBITDA margin of 19.2%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Results
Hussman Strategic Advisors Inc. invests $1.02 million in Medpace Holdings, Inc. (NASDAQ:MEDP).
Find jobs on Simplify and start your career today
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Irving, Texas
Founded
1992
Find jobs on Simplify and start your career today